ODTX Stock Analysis: Odyssey Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 807m USD | 12M Return: -3.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.82M
Rev. Trend: 69.9%
Warnings
Tailwinds
No distinct edge detected
Seasonality 0.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Odyssey Therapeutics, Inc. (NASDAQ: ODTX) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that develops medicines for autoimmune and inflammatory diseases. The company was incorporated in 2021 and operates from the Boston/Cambridge biotech cluster, a major hub for immunology research and biopharma venture funding.
Its pipeline is built around small-molecule and protein-based candidates targeting innate immune and inflammatory pathways. The lead asset, OD-001, is an oral small-molecule inhibitor of RIPK2 currently in a Phase 2a trial for ulcerative colitis. Additional programs include OD-002, an oral SLC15A4 inhibitor aimed at blocking TLR7/8/9-driven IRF5 activation; OD-003, a protein therapeutic designed to selectively agonize TNFR2 on regulatory T cells; a TSLP/IL-33 bispecific antagonist; an oral small-molecule IRAK4 scaffolding inhibitor; and a small-molecule IRF5 inhibitor.
As a clinical-stage biotechnology company, Odyssey does not yet have approved products or commercial revenue, and its operations are funded primarily through capital markets and R&D partnerships. Autoimmune and inflammatory diseases remain a large and active therapeutic area, with several kinase and innate-immune targets (such as IRAK4, RIPK2, and IRF5) being pursued by multiple drug developers.
- OD-001 Phase 2a ulcerative colitis data readout approaches
- Cash burn accelerates as clinical trials expand across pipeline
- Big pharma partnership or acquisition interest in inflammation assets
| Net Income: -76.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.30 > 0.02 and ΔFCF/TA 29.45 > 1.0 |
| NWC/Revenue: 8.49k% < 20% (prev 2.39k%; Δ 6.10k% < -1%) |
| CFO/TA -0.35 > 3% & CFO -79.7m > Net Income -76.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.33 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (27.6m) vs prev -41.58% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.90% > 50% (prev 2.27%; Δ -1.37% > 0%) |
| Interest Coverage Ratio: -7.05k > 6 (EBIT TTM -84.6m / Interest Expense TTM 12.0k) |
| A: 0.71 (Total Current Assets 185.1m - Total Current Liabilities 22.2m) / Total Assets 229.1m |
| B: -2.65 (Retained Earnings -606.4m / Total Assets 229.1m) |
| C: -0.40 (EBIT TTM -84.6m / Avg Total Assets 213.3m) |
| D: -0.70 (Book Value of Equity -523.7m / Total Liabilities 752.8m) |
| Altman-Z'' = -7.36 = D |
As of July 08, 2026, the stock is trading at USD 15.91 with a total of 229,207 shares traded. Over the past week, the price has changed by -15.78%, over one month by -7.07%, over three months by -3.11% and over the past year by -3.11%.
Current recommended Stop Loss: 13.80 (which is 13.3% or 1.6 ATR below the current price).
Odyssey Therapeutics has no consensus analysts rating.
P/S = 762.6901
Revenue TTM = 1.92m USD
EBIT TTM = -84.6m USD
EBITDA TTM = -82.1m USD
Long Term Debt = 20.8m USD (estimated: total debt 26.1m - short term 5.37m)
Short Term Debt = 5.37m USD (from shortTermDebt, last quarter)
Debt = 26.1m USD (from shortLongTermDebtTotal, last quarter) (leases 26.1m already included)
Net Debt = -149.6m USD (calculated: Debt 26.1m - CCE 175.7m)
Enterprise Value = 657.3m USD (806.9m + Debt 26.1m - CCE 175.7m)
Interest Coverage Ratio = -7.05k (Ebit TTM -84.6m / Interest Expense TTM 12.0k)
EV/FCF = -9.43x (Enterprise Value 657.3m / FCF TTM -69.7m)
FCF Yield = -10.61% (FCF TTM -69.7m / Enterprise Value 657.3m)
FCF Margin = -3.64k% (FCF TTM -69.7m / Revenue TTM 1.92m)
Net Margin = -4.00k% (Net Income TTM -76.7m / Revenue TTM 1.92m)
Gross Margin = unknown ((Revenue TTM 1.92m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.87 (Enterprise Value 657.3m / Total Assets 229.1m)
Interest Expense / Debt = 0.05% (Interest Expense 12.0k / Debt 26.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -66.8m (EBIT -84.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.08 (Total Current Assets 185.1m / Total Current Liabilities 30.4m)
Debt / Equity = -0.05 (negative equity) (Debt 26.1m / totalStockholderEquity, last quarter -523.7m)
Debt / EBITDA = 1.82 (negative EBITDA) (Net Debt -149.6m / EBITDA -82.1m)
Debt / FCF = 2.15 (negative FCF - burning cash) (Net Debt -149.6m / FCF TTM -69.7m)
Total Stockholder Equity = -488.3m (last fiscal year from totalStockholderEquity)
RoA = -35.97% (Net Income -76.7m / Total Assets 229.1m)
RoE = 15.71% (negative equity) (Net Income TTM -76.7m / Total Stockholder Equity -488.3m)
RoCE = 18.09% (negative capital employed) (EBIT -84.6m / Capital Employed (Equity -488.3m + L.T.Debt 20.8m))
RoIC = -31.50% (negative operating profit) (NOPAT -66.8m / Invested Capital 212.1m)
WACC = 0.00% (E(806.9m)/V(833.1m) * Re(0.0%) + D(26.1m)/V(833.1m) * Rd(0.05%) * (1-Tc(0.21)))
Discount Rate = 5.29% (= Risk Free + ERP)
Shares (yearly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Fair Price = unknown (Cash Flow -69.7m)
Revenue Correlation: 69.89 | Revenue CAGR: 69.41% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.85 | Chg30d=N/A | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.89 | Chg30d=N/A | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=-4.55 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.88 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+14.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +0% (up=0, down=0)